PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually..

加利福尼亚州帕萨迪纳（商业新闻短讯）--箭头制药公司（NASDAQ:ARWR）今天宣布，ARO-INHBE（一种基于rna干扰的肥胖和代谢疾病治疗药物）的临床前数据已于6月21日至24日在佛罗里达州奥兰多举行的美国糖尿病协会（ADA）第84届科学会议上公布。。

The preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been identified through large genetic studies as a promising target for next generation therapies to address obesity and metabolic diseases. Further, Arrowhead’s preclinical research suggests that INHBE knockdown may potentially lead to a suppression in body weight gain, loss of fat mass, and preservation of lean mass.

临床前结果表明，ARO-INHBE基本上沉默了INHBE基因的肝脏表达，该基因已通过大型遗传学研究被确定为下一代治疗肥胖和代谢疾病的有希望的靶标。。

Arrowhead plans to file for regulatory clearance in late 2024 to begin clinical studies of ARO-INHBE..

Arrowhead计划在2024年末申请监管许可，开始ARO-INHBE的临床研究。。

“There has been a great deal of progress with new agents to treat obesity and metabolic diseases, but significant loss of lean mass and adverse gastrointestinal events at higher dose levels have necessitated the identification of new therapeutic strategies with novel mechanisms of action,” said James Hamilton, M.D., chief of discovery and translational medicine at Arrowhead.

。

“ARO-INHBE directly targets hepatic expression of the INHBE gene. Prior genetic studies have associated loss of function mutations in the INHBE gene with reduced levels of abdominal fat and an improved metabolic profile. Our preclinical data presented at ADA suggest that INHBE reduction with siRNA is a promising new approach to address obesity and metabolic diseases and strongly support advancing ARO-INHBE into clinical trials.”.

“ARO-INHBE直接靶向INHBE基因的肝脏表达。先前的遗传学研究已经将INHBE基因的功能丧失突变与腹部脂肪水平降低和代谢特征改善相关联。我们在ADA上提供的临床前数据表明，用siRNA减少INHBE是一种解决肥胖和代谢疾病的有前途的新方法，并强烈支持将ARO-INHBE推进临床试验。”。

In pharmacological studies in obese and diabetic mouse models, INHBE siRNA administration resulted in multiple promising findings, including the following:

在肥胖和糖尿病小鼠模型的药理学研究中，INHBE siRNA给药产生了多个有希望的发现，包括以下内容：

95% reduction in INHBE mRNA expression

INHBE mRNA表达降低95%

19% suppression of body weight compared to saline controls

与生理盐水对照组相比，体重抑制了19%

26% loss of fat mass

脂肪量减少26%

Preservation of lean mass

瘦体重的保存

In addition, co-treatment of tirzepatide with INHBE siRNA allowed for the use of a lower tirzepatide dose without compromising its therapeutic effect. These encouraging results suggest that ARO-INHBE has the potential to be a novel therapeutic for metabolic disease.

此外，替罗西肽与INHBE siRNA的共同治疗允许使用较低的替罗西肽剂量而不损害其治疗效果。这些令人鼓舞的结果表明，ARO-INHBE有可能成为代谢疾病的新型治疗药物。

Details about the ADA presentations are listed below.

下面列出了有关ADA演示文稿的详细信息。

American Diabetes Association 84th Scientific Sessions – June 21-24, 2024

美国糖尿病协会第84届科学会议–2024年6月21日至24日

Title: Liver-specific silencing of INHBE with ARO-INHBE, an siRNA therapeutic, for metabolic diseases

Date: June 24, 2024

日期：2024年6月24日

Type: Poster

类型：海报

Arrowhead will discuss its growing pipeline of cardiometabolic medicines at two events as part of its 2024 Summer Series of R&D Webinars. The company’s lead clinical programs, including the recently completed PALISADE Phase 3 study in familial chylomicronemia with plozasiran, will be highlighted on June 25, 2024, and two preclinical programs addressing obesity and metabolic diseases, including ARO-INHBE, will be discussed on August 15, 2024..

作为2024年夏季系列研发网络研讨会的一部分，箭头将在两个活动上讨论其不断增长的心脏代谢药物管道。2024年6月25日将重点介绍该公司的主要临床项目，包括最近完成的PALISADE家族性乳糜微粒血症与普洛扎西兰的3期研究，2024年8月15日将讨论两个针对肥胖和代谢疾病的临床前项目，包括ARO-INHBE。。

The ADA presentation and the Summer Series of R&D Webinars may be accessed on the Events and Presentations page in the Investors section of the Arrowhead website.

ADA演示和夏季系列研发网络研讨会可以在箭头网站投资者部分的活动和演示页面上访问。

About Arrowhead Pharmaceuticals

关于箭头制药

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.

箭头制药公司（Arrowhead Pharmaceuticals）通过沉默导致顽固性疾病的基因来开发治疗顽固性疾病的药物。使用广泛的RNA化学组合和有效的递送方式，箭头疗法触发RNA干扰机制，以诱导靶基因的快速，深入和持久的敲低。

RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing..

RNA干扰（RNAi）是活细胞中存在的一种机制，可抑制特定基因的表达，从而影响特定蛋白质的产生。Arrowhead基于RNAi的疗法利用了这种基因沉默的自然途径。。

For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma or on LinkedIn. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

欲了解更多信息，请访问www.arrowheadharma.com，或通过X（以前的推特）关注我们@arrowheadharma或LinkedIn。要添加到公司的电子邮件列表并直接接收新闻，请访问http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

私人证券诉讼改革法案下的安全港声明：

This news release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款所指的前瞻性声明。除历史信息外，本版本中包含的任何声明都可能被视为前瞻性声明。。

In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements.

此外，任何涉及我们未来财务业绩预测、业务趋势、对我们产品线或候选产品的期望（包括预期的监管提交和临床计划结果）、我们与其他公司合作的前景或益处，或未来事件或情况的其他特征的声明都是前瞻性声明。

These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.

这些前瞻性陈述包括但不限于关于我们的临床前研究和临床试验以及我们的研究和开发计划的开始，时间，进展和结果的陈述；我们对合作伙伴关系、许可和/或合作安排以及我们已经达成或将来可能达成的其他战略安排和交易的潜在利益的期望；我们对里程碑、特许权使用费或现有协议下可能应付给第三方或来自第三方的其他付款的信念和期望；以及我们对未来收入、研发费用、资本要求和向第三方付款的估计。

These statements are based u.

这些声明基于美国。

Source: Arrowhead Pharmaceuticals, Inc.

来源：Arrowhead Pharmaceuticals，Inc。